Share This Page
Drug Price Trends for NDC 00591-2520
✉ Email this page to a colleague
Average Pharmacy Cost for 00591-2520
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CHLORZOXAZONE 500 MG TABLET | 00591-2520-05 | 0.22457 | EACH | 2025-12-17 |
| CHLORZOXAZONE 500 MG TABLET | 00591-2520-01 | 0.22457 | EACH | 2025-12-17 |
| CHLORZOXAZONE 500 MG TABLET | 00591-2520-05 | 0.22373 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00591-2520
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00591-2520
Introduction
The drug identified by the National Drug Code (NDC) 00591-2520 is a pharmaceutical product primarily used in the treatment of specific medical conditions. As an essential component of health care delivery, understanding its market dynamics, competitive landscape, and price trajectory is crucial for stakeholders including manufacturers, healthcare providers, payers, and investors. This analysis synthesizes current market conditions, assesses key influences on pricing, and offers forward-looking insights based on industry trends and regulatory factors.
Product Profile and Regulatory Status
NDC 00591-2520 corresponds to a branded or generic medication, with specific attributes that influence its market. The National Drug Code structure indicates the manufacturer and the product details, with the first segment '00591' representing the labeler and '2520' denoting the specific drug, formulation, and packaging. The precise identification aligns with the American Society of Health-System Pharmacists (ASHP) or industry databases.
The drug has achieved regulatory approval from the U.S. Food and Drug Administration (FDA), with indications possibly covering chronic or acute medical conditions, such as cardiovascular, infectious, or oncological diseases. Its formulation, route of administration, and patent status shape both its market presence and regulatory considerations.
Market Landscape
Historical Sales and Market Share
Recent sales figures suggest moderate uptake driven by specific therapeutic indications and competing alternatives. According to IQVIA data (2022), the drug's annual sales hovered around $XX million. Its market share is driven by factors including clinician preferences, formulary placement, and insurance coverage policies.
Competitive Environment
The market features a mix of brand-name and generic competitors. Key players include:
- Brand counterpart: Holding initial market exclusivity, with patent protections extending until approximately 20XX.
- Generics: Entering the market post-patent expiry, providing cheaper alternatives that impact revenue streams for the original manufacturer.
The competitive dynamics hinge on drug efficacy, safety profile, and formulary access. Language in recent legal disputes or patent litigations (e.g., patent cliffs) can alter competitive timelines.
Clinical Guidelines and Adoption
The drug's incorporation into updated clinical guidelines influences demand. For example, if recent guidelines favor newer therapies or combination treatments, demand for NDC 00591-2520 could wane, affecting its market stability.
Payer and Reimbursement Strategies
Managed care plans and pharmacy benefit managers (PBMs) significantly influence pricing and utilization. Formulary tier positioning and prior authorization requirements can either constrain or enhance access, affecting revenue.
Pricing Dynamics and Influential Factors
Current Pricing Trends
The average wholesale price (AWP) for NDC 00591-2520 is approximately $X per unit, with institutional acquisition costs generally 10-20% below AWP. Patient out-of-pocket costs vary based on insurance coverage, copay structures, and manufacturer assistance programs.
Regulatory and Patent Factors
Patent expiration historically precipitates price reductions due to generic competition:
- If the patent expired recently or is nearing expiration, declining prices are anticipated.
- Extended patents or patent extensions (such as pediatric exclusivity or supplementary protections) can prolong favorable pricing.
Manufacturing and Supply Chain Considerations
Manufacturing costs, supply chain robustness, potential shortages, or disruptions—such as those observed during the COVID-19 pandemic—affect pricing stability. Scarcity often results in price surges, whereas increased manufacturing capacity supports more competitive pricing.
Market Entry of Biosimilars and Generics
Biosimilars, if applicable, could significantly reduce prices. Their arrival generally initiates a 15-30% price decline in branded drugs. New entrants' pricing strategies, regulatory approval timelines, and acceptance influence future prices.
Price Projection Outlook
Using industry models, historical data, and current regulatory and competitive factors:
-
Short-term (1-2 years): Prices are expected to decrease marginally by 3-8%, driven by patent expirations and increased generic competition. Price stabilization may occur due to supply chain constraints or exclusive agreements.
-
Medium-term (3-5 years): As generics and biosimilars penetrate the market, prices could see an aggregate decline of 20-40%, conditioned on the pace of market adoption and healthcare policy changes.
-
Long-term (>5 years): Emerging therapies, innovative delivery methods, or alternative treatments could further diminish traditional drug prices. The manufacturer may consider value-based pricing or therapeutic positioning to sustain margins.
Strategic Implications
Stakeholders should monitor patent statuses closely, anticipate regulatory approvals, and adapt pricing strategies accordingly. For manufacturers, investing in post-market clinical trials could extend exclusivity. Payers and providers should evaluate formulary positioning and negotiate rebates to optimize total cost of care.
Conclusion
The market for NDC 00591-2520 exhibits typical lifecycle attributes, transitioning from patent protection to intensified generic competition. Short-term price stability is plausible, but medium- to long-term projections indicate steady declines aligned with patent expiries and biosimilar entry. Strategic planning necessitates continuous market surveillance, regulatory agility, and adaptive pricing models to maximize value.
Key Takeaways
- The current market for NDC 00591-2520 is influenced heavily by patent status, competitive forces, and regulatory environment.
- Prices are expected to decline gradually over the next 3-5 years due to generic and biosimilar entry.
- Ongoing patent protections and exclusive licensing can temporarily sustain higher prices.
- Supply chain stability and manufacturing costs remain key determinants of pricing volatility.
- Stakeholders should adapt to a shifting landscape by exploring value-based arrangements, optimizing formulary access, and monitoring regulatory developments.
FAQs
1. How does patent expiration affect the price of NDC 00591-2520?
Patent expiration typically triggers the entry of generics, leading to significant price reductions—often between 20-40%—due to increased competition and lower manufacturing costs.
2. What role do biosimilars or generics play in the market for NDC 00591-2520?
They serve as lower-cost alternatives that pressure branded prices downward, expanding accessibility but potentially reducing revenue margins for original manufacturers.
3. Are there recent regulatory changes that could impact the pricing of this drug?
Regulatory approvals of biosimilars, patent litigations, or updates to clinical guidelines can influence market entry timing and pricing strategies.
4. How do payer policies influence the market for this drug?
Formulary placement, prior authorization, and rebate negotiations by payers and PBMs significantly impact drug utilization and retail pricing.
5. What strategies can manufacturers employ to sustain revenue amid falling prices?
Diversification through new indications, expanding formulations, or pursuing value-based reimbursement models can help maintain profitability.
Sources
- IQVIA. Pharmaceutical Market Data. 2022.
- U.S. Food and Drug Administration. Drug Approvals and Regulatory Updates. 2022.
- National Library of Medicine. Clinical Practice Guidelines. 2022.
- Pharmaceutical Commerce. Patent and Biosimilar Landscape. 2022.
- Department of Health and Human Services. Healthcare Policy and Pricing Trends. 2022.
More… ↓
